## PART B -FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE

**Commissioner for Patents** P.O. Box 1450 Alexandria, Virginia 22313-1450

or Fax (571) 273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks I through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

TITLE OF INVENTION: RECEPTOR FUNCTION REGULATOR  APPLN. TYPE SMALL ENTITY ISSUE FEE PUBLICATION FEE TOTAL FEE(S) DUE DATE DUE  Non-Provisional no \$1,510.00 \$300.00 \$1,810.00 05/02/2011  EXAMINER ART UNIT CLASS-SUBCLASS  J. P. Cornet 1628 5-14-183000  1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.27 (20 Mg and part of the patent front page, list Correspondence address form PTO/SB/1/2) attacked.  Correspondence Address form PTO/SB/1/2) attacked.  Tee Address" indication of "Fee Address" findication of "Tee Address" indication of "Fee Address" indication of "Tee Address" indication on a send in the Indication of the Indication of Tee Address indication of the Tee Address indication on the Indication of Tee Address indication on the Indication of the Indication of Tee Address indication on the Indication of	CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)  EDWARDS ANGELL PALMER & DODGE LLP P.O. Box 55874  Boston, Massachusetts 02205  APPLICATION NO. FILING DATE FIRST NAMED INVENT					Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.  Certificate of Mailing or Transmission  I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.  (Depositor's name)  April 30, 2011 (Date)				
APPLN. TYPE SMALL ENTITY ISSUE FEE PUBLICATION FEE TOTAL FEE(S) DUE DATE DUE  Non-Provisional no S.L.510.00 \$300.00 \$1,810.00 05/02/2011  EXAMINER ART UNIT CLASS-SUBCLASS  J. P. Cornet 1628 514-183000  1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).  Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).  Change of correspondence address (or Change of Correspondence address (or Change of Correspondence Address form PTO/SB/42) attached.  The Address indication (or "Fee Address" Indication of "Fee Address" indication (or "Fee Address" Indication of "Fee Address" Indication (or "Fee Address" Indication (or "Fee Address" Indication (or "Fee Address" Indication on a seignet in a registered attached. Use of a Customer Number is required.  3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)  PLEASE NOTE: Unless an assignce is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filled for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filling an assignment.  (A) NAME OF ASSIGNEE (B) RESIDENCE (CITY and STATE OR COUNTRY)  Takeda Pharmaceutical Company Limited  Osaka, Japan  Please check the appropriate assignee category or categories (will not be printed on the patent): Individual X Corporation or other private group entity Government  4a. The following fee(s) are enclosed:  A publication Fee (No small entity discount permitted)  Advance Order # of Copies  X The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number  O4-1105  5. Change in Entity Status (from status indicated above)  Authorized Signature  Applicant claims SMALL ENTITY status. See 37 CFR 1.27 (E) Canny Or to	10/534,081	06/13/2005	06/13/2005		Kohji Fukatsu		66530(46590)		8962	
Non-Provisional   Non-Provis	TITLE OF INVENTION: RECEPTOR FUNCTION REGULATOR									
EXAMINER  1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.3630).  Change of correspondence address form PTO/SB/122) attached. The Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required.  3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)  PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignmen is 1 and 137 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.  (A) NAME OF ASSIGNEE  Takeda Pharmaceutical Company Limited  Pease check the appropriate assignee category or categories (will not be printed on the patent):  [B) RESIDENCE: (CITY and STATE OR COUNTRY)  Advance Order -# of Copies  Authorized Signature  (Mark D. Russett)  Authorized Signature  (Mark D. Russett)  Authorized Signature  (Mark D. Russett)  Date  April 30, 2011	APPLN. TYPE	SMALL ENTITY	ISSUE FEE		PUBLICATION FEE		TOTAL FEE(S) DUE		DATE DUE	
J. P. Cornet   1628   514-183000     1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).   Change of correspondence address (or Change of Correspondence Address for PTO/SB/122) attached.   Change of Correspondence Address for PTO/SB/122) attached.   Tee Address" indication (or "Fee Address" indication for "Fee Address" indication in a signer of a single firm (having as a member of up to 2 registered patent attorneys or agents. If no name will be printed.   David G. Conlin   Amark D. Russett    3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)  PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (CTTY and STATE OR COUNTRY)  Takeda Pharmaceutical Company Limited Osaka, Japan  Please check the appropriate assignee category or categories (will not be printed on the patent): Individual X Corporation or other private group entity Government  4a. The following fee(s) are enclosed: 4b. Payment of Fee(s):  X Issue Fee Advance Order -# of Copies X The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number O4-1105  5. Change in Entity Status (from status indicated above)  a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). he Director of the USPTO is requested to apply the Issue F					1		\$1,810.00		05/02/2011	
1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).  Change of correspondence address for Change of Correspondence address for Change of Correspondence Address from PTO/SB/122) attached.  The Address indication (or "Fee Address" Indication form PTO/SB/122) attached.  The Address indication (or "Fee Address" Indication form PTO/SB/147; Rev 0.30-20 or more recent) attached.  Use of a Customer Number is required.  3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)  PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.  (A) NAME OF ASSIGNEE  (B) RESIDENCE: (CITY and STATE OR COUNTRY)  Takeda Pharmaceutical Company Limited  Osaka, Japan  Please check the appropriate assignee category or categories (will not be printed on the patent): Individual X Corporation or other private group entity Government  4a. The following fee(s) are enclosed:  A check in the amount of the fee(s) is enclosed.  Yeublication Fee (No small entity discount permitted)  Advance Order -# of Copies  A dvance Order -# of Copies  The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number 04-1105  5. Change in Entity Status (from status indicated above)  a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27.  b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above.  Authorized Signature  // Mark D. Russett/  Date April 30, 2011										
Address* (37 CFR 1.363).  Change of correspondence address (or Change of Correspondence address form PTO/SB/122) attached.  Tee Address* indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required.  3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)  PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.  (A) NAME OF ASSIGNEE  Takeda Pharmaceutical Company Limited  Osaka, Japan  Please check the appropriate assignee category or categories (will not be printed on the patent): Individual X Corporation or other private group entity Government  4a. The following fee(s) are enclosed:  X Issue Fee  A check in the amount of the fee(s) is enclosed.  X Publication Fee (No small entity discount permitted)  Advance Order -# of Copies  A check in the amount of the fee(s) is enclosed.  X The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number  5. Change in Entity Status (from status indicated above)  a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27.  b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2).  The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. OTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in terest as shown by the records of the United States Patent and Trademark Office.				F					11 D 1 0 D 1	
PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.  (A) NAME OF ASSIGNEE  (B) RESIDENCE: (CITY and STATE OR COUNTRY)  Takeda Pharmaceutical Company Limited  Osaka, Japan  Please check the appropriate assignee category or categories (will not be printed on the patent): Individual x Corporation or other private group entity Government  4a. The following fee(s) are enclosed:    A check in the amount of the fee(s) is enclosed.   A check in the amount of the fee(s) is enclosed.   A publication Fee (No small entity discount permitted) Payment by credit card. Form PTO-2038 is attached.   Advance Order -# of Copies	Address* (37 CFR 1.363).  Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.  "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached.			(1) the names of up to 3 registered patent attorneys or agents OR, alternatively, (2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no  3 Mark D. Russett						
for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.  (A) NAME OF ASSIGNEE  (B) RESIDENCE: (CITY and STATE OR COUNTRY)  Takeda Pharmaceutical Company Limited  Osaka, Japan  Please check the appropriate assignee category or categories (will not be printed on the patent): Individual X Corporation or other private group entity Government  4a. The following fee(s) are enclosed:  X Issue Fee  A check in the amount of the fee(s) is enclosed.  X Publication Fee (No small entity discount permitted)  Payment by credit card. Form PTO-2038 is attached.  X The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number  O4-1105  5. Change in Entity Status (from status indicated above)  a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27.  b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2).  The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.  Authorized Signature  /Mark D. Russett/  Date  April 30, 2011										
Please check the appropriate assignee category or categories (will not be printed on the patent): Individual X Corporation or other private group entity Government  4a. The following fee(s) are enclosed:  X Issue Fee A check in the amount of the fee(s) is enclosed.  X Publication Fee (No small entity discount permitted) Payment by credit card. Form PTO-2038 is attached.  X The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number 04-1105  5. Change in Entity Status (from status indicated above)  a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27.  b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2).  The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above.  HOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.  Authorized Signature  /Mark D. Russett/  Date April 30, 2011	PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filling an assignment.									
4a. The following fee(s) are enclosed:  X Issue Fee  A check in the amount of the fee(s) is enclosed.  X Publication Fee (No small entity discount permitted)  Payment by credit card. Form PTO-2038 is attached.  Advance Order -# of Copies  Advance Order -# of Copies  The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number  04-1105  5. Change in Entity Status (from status indicated above)  a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27.  b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2).  The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above.  Authorized Signature  /Mark D. Russett/  Date  April 30, 2011	Takeda Pharmaceutical Company Limited Osaka, Japan									
X   Issue Fee	Please check the appropriate assignee category or categories (will not be printed on the patent): Individual X Corporation or other private group entity Government									
Advance Order -# of Copies  Advance Order -# of Copies  The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number  04-1105  5. Change in Entity Status (from status indicated above)  a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27.  b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2).  The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above.  NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.  Authorized Signature  /Mark D. Russett/  Date  April 30, 2011	4a. The following fee(s) are enclosed:  4b. Payment of Fee(s):									
Advance Order # of Copies  X The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number  04-1105  5. Change in Entity Status (from status indicated above)  a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27.  b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2).  The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above.  NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.  Authorized Signature  /Mark D. Russett/  Date  April 30, 2011	X Issue Fee		A check in the amount of the fee(s) is enclosed.							
Deposit Account Number 04-1105  5. Change in Entity Status (from status indicated above)  a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.  Authorized Signature /Mark D. Russett/ Date April 30, 2011	X Publication Fee (No small entity discount permitted) Payment by credit card. Form PTO-2038 is attached.									
a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27.  b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. IOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in the treest as shown by the records of the United States Patent and Trademark Office.  Authorized Signature	Advance Order	<u>x</u>								
The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above.  IOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.  Authorized Signature /Mark D. Russett/ Date April 30, 2011	5. Change in Entity Status (from status indicated above)									
Authorized Signature /Mark D. Russett/ Date April 30, 2011	a. Applicant clair	ns SMALL ENTITY sta	tus. See 37 CFR 1.2	27.	b. Applica	ant is no longer	claiming SMALL	ENTITY sta	atus. See 37 CFR 1.27(g)(2).	
	NOTE: The Issue Fee and I	Publication Fee (if require	d) will not be accepte	ed from a						
Typed or printed name Mark D. Russett Registration No. 41,281	Authorized Signature	·	/Mark D. Ru	O. Russett/			Date	Aj	oril 30, 2011	
	Typed or printed nam	ne	Mark D. Ru	issett			Registratio	on No.	41,281	